Carnegie Investment Counsel’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.85M Sell
11,834
-25
-0.2% -$3.75K 0.04% 257
2026
Q1
$1.81M Sell
11,859
-575
-5% -$88.1K 0.04% 266
2025
Q4
$1.71M Buy
12,434
+200
+2% +$26.2K 0.03% 273
2025
Q3
$1.57M Sell
12,234
-19
-0.2% -$2.32K 0.03% 273
2025
Q2
$1.48M Buy
12,253
+584
+5% +$65.8K 0.03% 269
2025
Q1
$1.2M Hold
11,669
0.03% 267
2024
Q4
$1.14M Sell
11,669
-200
-2% -$21.3K 0.03% 250
2024
Q3
$1.37M Buy
11,869
+832
+8% +$94.4K 0.04% 241
2024
Q2
$1.18M Buy
11,037
+2
+0% +$201 0.04% 256
2024
Q1
$1.07M Sell
11,035
-535
-5% -$54.9K 0.03% 282
2023
Q4
$1.17M Sell
11,570
-52
-0.4% -$5.02K 0.04% 261
2023
Q3
$1.18M Sell
11,622
-325
-3% -$33K 0.05% 252
2023
Q2
$1.21M Sell
11,947
-28
-0.2% -$2.8K 0.04% 260
2023
Q1
$1.1M Sell
11,975
-500
-4% -$43.7K 0.04% 276
2022
Q4
$1.13M Sell
12,475
-46
-0.4% -$3.87K 0.05% 265
2022
Q3
$952K Buy
12,521
+391
+3% +$32.4K 0.05% 268
2022
Q2
$1.02M Buy
12,130
+235
+2% +$20.6K 0.05% 255
2022
Q1
$1.04M Sell
11,895
-21
-0.2% -$1.82K 0.04% 264
2021
Q4
$1.04M Buy
11,916
+800
+7% +$66.4K 0.03% 266
2021
Q3
$909K Hold
11,116
0.03% 257
2021
Q2
$1.01M Buy
11,116
+252
+2% +$22.4K 0.04% 250
2021
Q1
$929K Sell
10,864
-300
-3% -$26.9K 0.04% 250
2020
Q4
$1.05M Sell
11,164
-705
-6% -$61.6K 0.05% 225
2020
Q3
$1.03M Sell
11,869
-20
-0.2% -$1.73K 0.05% 212
2020
Q2
$1.04M Hold
11,889
0.06% 212
2020
Q1
$979K Sell
11,889
-35
-0.3% -$3.12K 0.07% 199
2019
Q4
$1.13M Hold
11,924
0.07% 214
2019
Q3
$1.04M Sell
11,924
-425
-3% -$38.2K 0.07% 215
2019
Q2
$1.13M Sell
12,349
-1,675
-12% -$142K 0.07% 203
2019
Q1
$1.21M Sell
14,024
-669
-5% -$53.7K 0.08% 198
2018
Q4
$1.13M Sell
14,693
-2,016
-12% -$157K 0.11% 185
2018
Q3
$1.31M Buy
16,709
+2,256
+16% +$167K 0.11% 178
2018
Q2
$1.06M Sell
14,453
-668
-4% -$46.1K 0.08% 200
2018
Q1
$1.05M Sell
15,121
-138
-0.9% -$10.5K 0.09% 190
2017
Q4
$1.16M Buy
15,259
+2,890
+23% +$218K 0.1% 199
2017
Q3
$952K Sell
12,369
-147
-1% -$11.1K 0.11% 184
2017
Q2
$956K Sell
12,516
-112
-0.9% -$7.94K 0.12% 182
2017
Q1
$892K Sell
12,628
-1,213
-9% -$80.8K 0.11% 181
2016
Q4
$914K Buy
13,841
+112
+0.8% +$7.26K 0.12% 172
2016
Q3
$930K Sell
13,729
-7,159
-34% -$522K 0.13% 161
2016
Q2
$1.55M Buy
20,888
+474
+2% +$32.7K 0.22% 121
2016
Q1
$1.32M Buy
20,414
+614
+3% +$41.8K 0.2% 127
2015
Q4
$1.38M Buy
19,800
+1,829
+10% +$145K 0.24% 109
2015
Q3
$1.45M Buy
17,971
+1,819
+11% +$162K 0.25% 99
2015
Q2
$1.42M Buy
16,152
+3,210
+25% +$294K 0.25% 99
2015
Q1
$1.2M Buy
12,942
+1,525
+13% +$135K 0.21% 114
2014
Q4
$974K Buy
11,417
+335
+3% +$27.8K 0.18% 127
2014
Q3
$935K Sell
11,082
-642
-5% -$51.9K 0.19% 129
2014
Q2
$951K Buy
11,724
+151
+1% +$11.9K 0.22% 107
2014
Q1
$882K Hold
11,573
0.23% 99
2013
Q4
$834K Sell
11,573
-89
-0.8% -$6.19K 0.22% 105
2013
Q3
$802K Buy
11,662
+530
+5% +$35.1K 0.25% 99
2013
Q2
$705K Buy
+11,132
New +$724K 0.23% 105

Other funds holding NVS

Carnegie Investment Counsel's NVS Position: Q2 2026 in Review

Carnegie Investment Counsel reduced its Novartis (NVS) stake by 0.21% in Q2 2026, selling an estimated $3.75K and leaving 11,834 shares worth $1.85M. The position accounts for 0.04% of the portfolio, ranked #257.

Carnegie Investment Counsel first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. 1,027 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Carnegie Investment Counsel held 11,834 shares of Novartis worth $1.85M as of Q2 2026.
  • Carnegie Investment Counsel sold 25 Novartis shares in Q2 2026, an estimated $3.75K.
  • Novartis made up 0.04% of Carnegie Investment Counsel's portfolio in Q2 2026, its #257 holding.
  • Carnegie Investment Counsel first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • 1,027 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.